TGFB1 and metabolic dysfunction-associated steatotic liver disease: Because the prevalence of obesity, MASLD, MASH, and obesity-related cancer continues to rise, integrating VNS into targeting TGF-β therapeutic strategies offers a cutting-edge approach to combat these interrelated conditions.